RankingsPricing
  1. US-listed companies
  2. Ultragenyx Pharmaceutical Inc.
  3. Raw

Ultragenyx Pharmaceutical Inc.RARE

Market cap
$3.1B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Cash and cash equivalents2494161100113434714308133214174
Marketable debt securities------488433615364436
Accounts receivable, net---5133323284073122
Inventory---17121316273445
Prepaid expenses and other assets61320294351587269-40
Other assets---------48-
Total current assets1934504022705228511,295857884732817
Property, Plant and Equipment, Net371722204474141260291266
Marketable debt securities------11259149200135
Intangible assets, net---142129129131131160166178
Goodwill---4444444444444444
Other assets112143921175863
Total assets1985605414917201,1351,7601,5221,5451,4911,503
Accounts payable535912131317434239
Accrued liabilities82555616283108146205196241
Lease liabilities-----7----10
Liabilities for sales of future royalties---------2950
Other liabilities----------4
Total current liabilities1328607175103190181261280344
Lease liabilities-----30----30
Deferred tax liabilities------3333323030
Liabilities for sales of future royalties-----315336352875862820
Other liabilities11655--151217
Total liabilities1328671071114826056001,1931,2161,241
Noncontrolling interest----------7
Common Stock, Value, Issued00000000000
Treasury stock, at cost, 69,757 in 2024 and 9,559 in 2023---------04
Deferred compensation obligation---------04
Additional paid-in capital3248171,0041,2221,6402,0872,7732,9973,1403,6624,213
Accumulated other comprehensive (loss) income-0-11-6-1-01-1-71-1
Accumulated deficit-139-285-531-833-1,030-1,433-1,620-2,074-2,781-3,388-3,957
Total stockholders’ equity1855314743836096541,154923352275255
Total liabilities, noncontrolling interest and stockholders' equity1985605414917201,1351,7601,5221,5451,4911,503